Investment Caution for Foldable Phones, Hair Loss Drug Stocks

Foldable phones have a very low profit margin of 5-6%, which has little impact on corporate profitability.

The expected production volume of Apple's foldable phones also remains lower than market expectations, with foldable phones accounting for only 3-4% of the total smartphone market. No significant benefits for foldable-related stocks were confirmed in the second-quarter earnings announcements, dampening investor sentiment.

While Samsung Electronics has pioneered the foldable phone market for five years, related component companies have not benefited as much as expected. Unlike Foxconn, which was re-evaluated for AI device outsourcing, it is analyzed that foldable component companies struggle to translate stock price momentum into actual earnings.

It is assessed that expectations for foldable phone related stocks have already been reflected in their prices, but the level of reflection is minimal, making it difficult for a long-term trend to emerge.

The hair loss treatment market has high expectations for potential CAPA (production capacity), but uncertainty is very high in the early stages of clinical trials. Unlike obesity treatments, efficacy verification is not yet sufficient.

It is pointed out that such thematic bio investments should be approached strictly from a short-term trading perspective, and the risks are too high for long-term investment.

Honam semiconductors are expected to sufficiently benefit from the perspective of semiconductor factory infrastructure establishment. However, individual stocks require caution in investment due to strong sector-specific movements.

It is analyzed that investing in the semiconductor materials, parts, and equipment (Sooboojang) sector is more advantageous than directly looking at Honam semiconductor-related stocks.